HUTCHMED (China) (HCM) Non-Current Deferred Tax Liability (2014 - 2025)
HUTCHMED (China) (HCM) posted quarterly Non-Current Deferred Tax Liability of $255000.0 for Q4 2025, down 91.47% year-over-year from $3.0 million in Q4 2024, and down 91.47% quarter-over-quarter from $3.0 million in Q4 2024.
HUTCHMED (China) (HCM) Non-Current Deferred Tax Liability (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has reported Non-Current Deferred Tax Liability for 12 consecutive years, with $255000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 91.47% year-over-year to $255000.0; the TTM figure through Dec 2025 stood at $255000.0 (down 91.47% YoY), while the FY2025 annual figure was $255000.0, down 91.47% from the prior year.
- Non-Current Deferred Tax Liability eased to $255000.0 in Q4 2025 per HCM's latest filing, from $3.0 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $3.0 million in Q4 2024 and bottomed at $255000.0 in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $2.0 million across 5 years, with a median of $2.7 million in 2022.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability surged 101.48% — and 2025, when it slumped 91.47%.
- HUTCHMED (China)'s Non-Current Deferred Tax Liability stood at $2.8 million in 2021, then dropped by 1.99% to $2.7 million in 2022, then sank by 45.24% to $1.5 million in 2023, then soared by 101.48% to $3.0 million in 2024, then plunged by 91.47% to $255000.0 in 2025.
- Business Quant data shows HCM's Non-Current Deferred Tax Liability at $255000.0 in Q4 2025, $3.0 million in Q4 2024, and $1.5 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | HUTCHMED (China) | 2.19 Bn | 2.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Jun 30, 2018 | 5.05 Mn |
| Jun 30, 2018 | 5.05 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Dec 31, 2017 | 3.82 Mn |